Sclera

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Retrieved on: 
Thursday, April 18, 2024
Eurostat, Diagnosis, Civil service commission, Optic nerve, Brain, Pressure, Cell, Disease, Risk, Patient, Committee, Knowledge, Regulation, Cancer, EMA, IRIS, Scar, Eye, Wound healing, European, Allergic conjunctivitis, COMP, Collagen, Skin, European Commission, Safety, Glaucoma, Sclera, Pharmaceutical industry

Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Key Points: 


Orphan designation: Tranilast Prevention of scarring post glaucoma filtration surgery, 27/07/2010 Positive

Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency

Retrieved on: 
Monday, April 8, 2024
Patient, Cerebrovascular disease, Stroke, Accelerated approval (FDA), European Medicines Agency, Doctor of Philosophy, Osteomalacia, PROMIS, Therapy, Conditional, Natural history, CTX, Pros, ADAS, Risk, DSM-IV codes, Cohort, Aes, Alkaline phosphatase, Rickets, EMA, PXE, Safety, Epilepsy, Clinical trial, Food, Hospital, Disability, BSAP, Cardiovascular disease, Disease, PD, Paresis, Consultant, Hypophosphatemia, Fatigue, Survivor, Sclera, FDA, Observational study, Pyrophosphate, Choroid, Incidence, Retina, Biomarker, Life, Event, Medical imaging

BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced positive topline safety, pharmacokinetic (PK), pharmacodynamic (PD) and exploratory efficacy data from the Company’s ongoing Phase 1/2 clinical trials of INZ-701 in adults with ABCC6 Deficiency (PXE, pseudoxanthoma elasticum) and ENPP1 Deficiency.

Key Points: 
  • “We are excited by the excellent safety and preliminary efficacy profile of INZ-701 in adults with ABCC6 Deficiency,” said Douglas A. Treco, Ph.D., CEO of Inozyme Pharma.
  • The patients were assigned to three dose cohorts of INZ-701: 0.2 mg/kg (n=3), 0.6 mg/kg (n=3), and 1.8 mg/kg (n=4).
  • For trial design details, please see the section entitled “INZ-701 in ABCC6 Deficiency Phase 1/2 Clinical Trial Design” below.
  • For trial design details, please see the section entitled “INZ-701 in ENPP1 Deficiency Phase 1/2 Clinical Trial Design” below.

Professor Marshall Continues to Propel Ace Vision Group Forward

Retrieved on: 
Thursday, April 4, 2024
Retina, Food and Drug Administration, Presbyopia, Approximation error, Diabetes, Patient, Public, Light, Research, Doctor of Philosophy, University College London, Eye, LSM, Sclera, Food, FDA, Ageing, Telescopic sight

BOSTON, April 4, 2024 /PRNewswire/ -- Ace Vision Group, Inc., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology.

Key Points: 
  • Ace Vision Group Names Renown Eye Laser Pioneer John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology
    BOSTON, April 4, 2024 /PRNewswire/ -- Ace Vision Group, Inc ., an emerging medical device company at the forefront of pioneering rejuvenation therapy for the aging eye, today announced that it has named John Marshall, PhD, FRCPath, FMedSc as Scientific Advisor of Laser Technology.
  • Professor Marshall is a pioneer of laser eye surgery, having developed computer-controlled excimer lasers for the correction of human refractive errors, creating a new field of eye surgery.
  • "We are honored to add Professor Marshall who is so central in the field of eye lasers," said Dr. AnnMarie Hipsley, CEO of Ace Vision Group.
  • "Professor Marshall has already been a valuable supporter on our journey, and we are thrilled that he is assuming an official position on our team to propel us forward as we introduce our ground-breaking ophthalmic laser therapeutic for the age-related vision loss that comes with presbyopia."

CorNeat EverPatch Hits the US Market: Farewell to Traditional Ocular Tissue Grafts

Retrieved on: 
Tuesday, February 27, 2024
Cataract, FDA, Surgeon, ASCRS, Entrepreneurship, Safety, Refractive surgery, Society, Sclera, AGS, American Glaucoma Society

RA'ANANA, Israel, Feb. 27, 2024 /PRNewswire/ -- CorNeat Vision, a leader in innovative medical device solutions, proudly introduces the CorNeat EverPatch, a pioneering synthetic tissue-integrating matrix designed to revolutionize ophthalmic surgeries. Endorsed by leading surgeons across the US, this FDA-cleared device represents a significant leap forward in addressing complications related to surgical interventions of the ocular surface.

Key Points: 
  • The CorNeat EverPatch is a synthetic tissue substitute for ocular surface surgeries, offering a unique combination of features that provide a significant advantage over existing tissue grafts, which degrade over time.
  • The CorNeat EverPatch is poised to provide an optimal solution for reinforcing tissue over glaucoma drainage devices, addressing complications such as tube exposure that often require reoperation.
  • Dr. Gilad Litvin, Co-Founder and Chief Medical Officer at CorNeat Vision, emphasizes the safety and efficacy of the CorNeat EverPatch, stating, "Our synthetic tissue substitute is tear-resistant, non-degradable, and completely bio-compatible, with no observed chronic inflammatory response that exists around tissue grafts.
  • We are confident that the CorNeat EverPatch will set a new standard of care in ocular surgeries necessitating scleral reinforcement."

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Everads Enters License Agreement with Kriya for Development of Ocular Gene Therapy Candidates Using Everads' Suprachoroidal Delivery Technology

Retrieved on: 
Wednesday, September 27, 2023
Sclera, Eye, TEL, Choroid, Translational Vision Science & Technology, Kriyā, Retina, Pharmaceutical industry, Medical device

The agreement follows a research collaboration between the parties whereby Everads' platform was evaluated for delivery of the company's gene therapy candidates in non-human primate models.

Key Points: 
  • The agreement follows a research collaboration between the parties whereby Everads' platform was evaluated for delivery of the company's gene therapy candidates in non-human primate models.
  • Under the terms of the agreement, Kriya was granted field-based exclusivity for use of Everads' platform using gene therapy against certain prespecified therapeutic targets including ophthalmic diseases that involve the complement cascade, while Everads retains the right to continue using and/or licensing its technology to other parties for the development of other therapeutic targets using gene therapy, as well as all non-gene therapy applications.
  • Everads received an undisclosed upfront payment and is entitled to receive development milestones and royalties on net sales of products using Everads' platform.
  • "We are extremely excited to enter into this license agreement after a thorough evaluation of our technology and its applicability for delivery of gene therapy.

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

Retrieved on: 
Wednesday, September 27, 2023
Drug delivery, Retina, Injection, CR2, Pediatrics, IgG4-related ophthalmic disease, Sclera, Eye, Geographic atrophy, Quality of life, Intravitreal injection, Inflammation, AAV, Complement, RESEARCH, Administration, C3, Choroid, Stanford University School of Medicine, Patient, CR1, PARK, Entrepreneurship, FDA, Therapy, Emotional dysregulation, Disease, Pharmaceutical industry, Medical device, Vaccine, Ophthalmology, Kriyā, C5

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device. Everads is a private biotech company that has developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space, an anatomical compartment located between the sclera and choroid that traverses the circumference of the posterior segment of the eye. Suprachoroidal delivery is an emerging, non-surgical route of administration in ophthalmology. Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.

Key Points: 
  • Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.
  • The transaction enables Kriya’s access to Everads’ suprachoroidal delivery technology to deliver multiple prespecified gene therapy product candidates for several ophthalmic diseases, including those involving the complement cascade.
  • “I am quite optimistic and convinced that innovative therapies will continue to improve the lives of people with geographic atrophy and other serious ophthalmic diseases.
  • A gene therapy targeting the C3 and C5 pathways delivered by a suprachoroidal injection may be a significant improvement in the treatment of geographic atrophy.”

Banuba Presents Virtual Contact Lenses Try-On

Retrieved on: 
Wednesday, June 28, 2023
Other Retail, Online Retail, Internet, Luxury, Optical, Apps, Applications, Technology, Artificial Intelligence, Fashion, Cosmetics, Retail, Other Technology, Health, Contact, Sclera, Lens, Lighting, Iris, Pupil, Telescopic sight

Banuba, a cutting-edge AI and computer vision company, announced today the launch of its updated contact lenses try-on .

Key Points: 
  • Banuba, a cutting-edge AI and computer vision company, announced today the launch of its updated contact lenses try-on .
  • The new version is a part of TINT , Banuba's larger virtual try-on platform, and is designed to give users the ability to try on any kind of contact lenses, with the ability to recolor the iris, pupil, and sclera together or separately.
  • Banuba contact lenses virtual try-on is a game-changer for the fashion industry.
  • Banuba is excited to bring this new technology to the market and looks forward to continuing to innovate in the virtual try-on space.

FDA Clears CorNeat EverPatch, World's First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery

Retrieved on: 
Monday, June 12, 2023
US Foods, Surgeon, Sclera, Membrane, Patient, Risk, Entrepreneurship, Matrix, Health, FDA, News, Pharmaceutical industry

RA'ANANA, Israel, June 12, 2023 /PRNewswire/ -- CorNeat Vision's EverPatch, a synthetic tissue substitute, has been granted 510(k) clearance by the US Food & Drug Administration (FDA). The CorNeat EverPatch is the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface. This groundbreaking synthetic tissue substitute is designed to address the critical needs of ocular surgeons, providing a sterile and non-degradable solution for patients worldwide.

Key Points: 
  • RA'ANANA, Israel, June 12, 2023 /PRNewswire/ -- CorNeat Vision's EverPatch, a synthetic tissue substitute, has been granted 510(k) clearance by the US Food & Drug Administration (FDA).
  • The CorNeat EverPatch is the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries.
  • This groundbreaking synthetic tissue substitute is designed to address the critical needs of ocular surgeons, providing a sterile and non-degradable solution for patients worldwide.
  • The CorNeat EverPatch will be launched initially in leading ophthalmic centers in the U.S. in Q3 2023, expanding nationwide later in the year.

FDA Clears CorNeat EverPatch, World's First Non-degradable, Synthetic Tissue Substitute for Ophthalmic Surgery

Retrieved on: 
Thursday, June 8, 2023
US Foods, Surgeon, Sclera, Membrane, Patient, Risk, Entrepreneurship, Matrix, Health, FDA, News, Pharmaceutical industry

RA'ANANA, Israel, June 8, 2023 /PRNewswire/ -- CorNeat Vision's EverPatch, a synthetic tissue substitute, has been granted 510(k) clearance by the US Food & Drug Administration (FDA). The CorNeat EverPatch is the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue and is intended to reinforce the sclera and aid the physical reconstruction of the ocular surface. This groundbreaking synthetic tissue substitute is designed to address the critical needs of ocular surgeons, providing a sterile and non-degradable solution for patients worldwide.

Key Points: 
  • RA'ANANA, Israel, June 8, 2023 /PRNewswire/ -- CorNeat Vision's EverPatch, a synthetic tissue substitute, has been granted 510(k) clearance by the US Food & Drug Administration (FDA).
  • The CorNeat EverPatch is the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries.
  • This groundbreaking synthetic tissue substitute is designed to address the critical needs of ocular surgeons, providing a sterile and non-degradable solution for patients worldwide.
  • The CorNeat EverPatch will be launched initially in leading ophthalmic centers in the U.S. in Q3 2023, expanding nationwide later in the year.